Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, has announced its participation in the upcoming Evercore China Biotech Summit scheduled for August 19-21, 2025 in Shanghai, China.
The company's management will engage in a fireside chat with the Evercore ISI Research team and conduct one-on-one meetings with investors during the conference. Interested investors can arrange meetings through their Evercore representatives.
Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
The company's management team will be available for one-on-one meetings with investors throughout the conference. Interested investors should contact their BTIG representative to schedule meetings.
Ascentage Pharma (NASDAQ: AAPG) has successfully completed an offshore placement of 22 million ordinary shares at HKD68.60 per share. The placement was conducted by Dajun Yang Dynasty Trust, affiliated with the company's CEO. In a related transaction, the company will issue the same number of replacement shares to the trust, generating net proceeds of approximately HKD1,492 million (US$190.1 million).
The newly issued shares represent 6.29% of the company's pre-placement share capital. The proceeds will fund commercialization efforts, global clinical development of core pipeline candidates, and strengthen global operations. The transaction, managed by J.P. Morgan and Citigroup, was conducted outside the U.S. to non-U.S. persons under Regulation S.
Ascentage Pharma (NASDAQ: AAPG) has announced the pricing of a significant share placement involving 22 million ordinary shares at HKD68.60 per share. The placement, conducted by CEO Dajun Yang's affiliated trust, will generate gross proceeds of approximately HKD1,509.2 million (US$192.3 million).
The highly successful offshore placement was oversubscribed by eight times and is expected to close on July 17, 2025. Following the placement, the CEO's trust will subscribe to an equal number of new shares at the same price. The company plans to use the proceeds for commercialization efforts, global clinical development of core pipeline candidates, and strengthening global operations.
Ascentage Pharma (NASDAQ: AAPG) has announced a proposed top-up placement involving two key transactions. First, Dajun Yang Dynasty Trust, affiliated with the company's CEO, will offer ordinary shares in an offshore transaction to non-U.S. persons under Regulation S. Second, the Trust will subscribe to new company shares (Replacement Shares) at the same quantity and price as the offshore placement.
The proceeds from this offering will fund commercialization efforts, global clinical development of core pipeline candidates, and strengthen global operations. The placement shares will not be registered under U.S. Securities Act and won't be offered to the public in Hong Kong.
Ascentage Pharma (NASDAQ: AAPG) has achieved a significant milestone with the China NMPA approval of lisaftoclax, its novel Bcl-2 inhibitor, for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received prior systemic therapy including BTK inhibitors.
The approval is based on a pivotal Phase II study where lisaftoclax demonstrated compelling efficacy and favorable safety profile, with no tumor-lysis syndrome and manageable toxicities. This makes lisaftoclax the first Bcl-2 inhibitor approved in China for CLL/SLL treatment and only the second globally.
The drug addresses a significant unmet need in China, where CLL/SLL incidence is rising rapidly with younger onset age. Lisaftoclax was recently included in the 2025 Chinese Society of Clinical Oncology Guidelines, and Ascentage is currently conducting four global Phase III trials exploring additional indications.
Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, has announced two key executive appointments. Dr. Veet Misra joins as Chief Financial Officer, bringing over 20 years of investment banking experience and a unique combination of scientific background and capital markets expertise. Eric Huang has been appointed as Senior Vice President of Global Corporate Development and Finance, contributing his extensive experience from roles at Beigene and Novartis.
Both executives will report directly to CEO Dr. Dajun Yang and are expected to play crucial roles in the company's global expansion strategy. The dual-listed company (HKEX: 6855) is positioning itself as a leader in apoptosis-targeted therapies and aims to strengthen its presence in both Asian and U.S. markets.